PERKINELMER INC Stock Price, News & Analysis

PerkinElmer (NYSE: PKI) announced the launch of the Anti-SARS-CoV-2 QuantiVac^TM ELISA (IgG) by its subsidiary EUROIMMUN, a quantitative test for IgG antibodies against the SARS-CoV-2 S1 antigen. This assay supports vaccine development and may help assess immunity in previously infected individuals. EUROIMMUN aims to file for FDA Emergency Use Authorization (EUA). Production capacity has increased to over three million tests weekly, facilitating significant contributions to global epidemiological studies.

PerkinElmer (NYSE: PKI) will participate in the Wolfe Virtual Healthcare Conference on November 19 at 11:25 a.m. ET. The company's CEO, Prahlad Singh, is set to provide an update on the company's strategic priorities. A live audio webcast can be accessed through the Investors section of PerkinElmer's website, where a replay will also be available for 90 days after the event. PerkinElmer reported approximately $2.9 billion in revenue in 2019, employing about 13,000 people globally.

PerkinElmer, a leader in health innovation, announced its participation in the Stifel Virtual Healthcare Conference on November 17, 2020, at 1:20 p.m. ET. Jamey Mock, SVP and CFO, will discuss the company's strategic priorities and updates. A live audio webcast will be accessible on the company’s Investors webpage, with a replay available for 90 days post-event. In 2019, PerkinElmer reported revenues of approximately $2.9 billion and has a workforce of around 13,000 employees across 190 countries.

PerkinElmer (NYSE: PKI) has announced a recommended all-cash offer to acquire Horizon Discovery Group (LSE: HZD) for approximately $383 million. This acquisition, expected to close in Q1 2021, aims to enhance PerkinElmer's life sciences portfolio with gene editing and gene modulation tools. Horizon, headquartered in the UK, generated $75.5 million in revenue in 2019 and specializes in CRISPR and RNAi technologies. PerkinElmer anticipates the acquisition will modestly boost non-GAAP earnings in the first year and position Horizon favorably in a growing market.

PerkinElmer (NYSE: PKI) announced that its PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel has been cleared for marketing as an in vitro diagnostic device in over 30 countries, complying with the European In Vitro Diagnostic Directive. The test, currently under U.S. FDA review for Emergency Use Authorization, enables detection of SARS-CoV-2, influenza A, influenza B, and RSV from a single sample, crucial for coping with increased testing demands during flu season. The panel is designed to work with PerkinElmer's automated systems for enhanced efficiency in virus detection.

The Board of Directors of PerkinElmer (NYSE: PKI) has declared a quarterly dividend of $0.07 per share, payable on February 12, 2021, to shareholders of record by January 22, 2021. This announcement highlights the company's commitment to returning value to its shareholders.

PerkinElmer reported revenue of approximately $2.9 billion in 2019, employing about 13,000 staff across 190 countries. The company is a key player in the S&P 500 Index.

PerkinElmer, Inc. (NYSE: PKI) projects a 35% increase in reported revenue and a 33% rise in organic revenue for Q3 2020, driven by strong demand for its COVID-19 testing solutions, contributing approximately $280 million to the quarterly revenue. The financial results will be disclosed after market close on October 28, 2020, followed by a conference call hosted by the executive team.

PerkinElmer (NYSE: PKI) announced a partnership with the American Society of Hematology to enhance newborn screening for sickle cell disease (SCD) in sub-Saharan Africa. Approximately 120 million people globally have SCD, with a significant number in Africa, where many children die before age five due to the disease. The collaboration aims to screen 10,000-20,000 newborns annually in participating countries, improving early detection and treatment. This initiative will leverage resources for education, clinical interventions, and advocacy through the Consortium on Newborn Screening in Africa (CONSA).